世界の肺薬物送達システム市場2020-2025:ネブライザー、ドライパウダー吸入器(DPI)、定量吸入器(MDI)

【英語タイトル】Global Pulmonary Drug Delivery Systems Market Growth 2020-2025

LP Informationが出版した調査資料(LPI20AP6682)・商品コード:LPI20AP6682
・発行会社(調査会社):LP Information
・発行日:2020年2月11日
・ページ数:159
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
・産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single UserUSD3,660 ⇒換算¥391,620見積依頼/購入/質問フォーム
Multi UserUSD5,490 ⇒換算¥587,430見積依頼/購入/質問フォーム
Corporate UserUSD7,320 ⇒換算¥783,240見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
「肺薬物送達システムの世界市場」は、地域的には米州、アジア、欧州、中東・アフリカ市場をカバーしており、種類別には、ネブライザー、ドライパウダー吸入器(DPI)、定量吸入器(MDI)など、用途別には、COPD、喘息、その他などに区分してまとめた調査レポートです。肺薬物送達システムのグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が含まれています。
・肺薬物送達システムの世界市場概要(サマリー)
・肺薬物送達システムの企業別販売量・売上
・肺薬物送達システムの企業別市場シェア
・肺薬物送達システムの世界市場規模 2015年-2020年:種類別(ネブライザー、ドライパウダー吸入器(DPI)、定量吸入器(MDI))
・肺薬物送達システムの世界市場規模 2015年-2020年:用途別(COPD、喘息、その他)
・肺薬物送達システムの米州市場規模(アメリカ、カナダ、メキシコなど)
・肺薬物送達システムのアジア市場規模(日本、中国、韓国、インド、東南アジアなど)
・肺薬物送達システムの欧州市場規模(ドイツ、フランス、イギリス、イタリア、ロシアなど)
・肺薬物送達システムの中東・アフリカ市場(エジプト、南アフリカ、トルコ、GCC諸国など)
・肺薬物送達システム市場の成長要因・課題・動向
・肺薬物送達システムの世界市場予測 2021年-2025年
・肺薬物送達システムの米州市場予測(アメリカ、カナダ、メキシコなど)
・肺薬物送達システムのアジア市場予測(日本、中国、韓国、インド、東南アジアなど)
・肺薬物送達システムの欧州市場予測(ドイツ、フランス、イギリス、イタリア、ロシアなど)
・肺薬物送達システムの中東・アフリカ市場予測(エジプト、南アフリカ、トルコ、GCC諸国など)
・肺薬物送達システムの世界市場予測:種類別(ネブライザー、ドライパウダー吸入器(DPI)、定量吸入器(MDI))
・肺薬物送達システムの世界市場予測:用途別(COPD、喘息、その他)
・主要企業分析
【レポートの概要】

According to this study, over the next five years the Pulmonary Drug Delivery Systems market will register a 4.4% CAGR in terms of revenue, the global market size will reach $ 3244.5 million by 2025, from $ 2735.7 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Pulmonary Drug Delivery Systems business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Pulmonary Drug Delivery Systems market by type, application, key manufacturers and key regions and countries.

This study considers the Pulmonary Drug Delivery Systems value and volume generated from the sales of the following segments:

Segmentation by type: breakdown data from 2015 to 2020, in Section 2.3; and forecast to 2025 in section 11.7.
Nebulizers
Dry Powder Inhaler (DPI)
Metered Dose Inhaler (MDI)

Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2024 in section 11.8.
COPD
Asthma
Others

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
3M
Omron Healthcare
GSK
Cipla
Chiesi
AstraZeneca
Novartis
Boehringer Ingelheim
Philips Respironics
Aptar
Chia Tai Tianqing
PARI
Shanghai Huarui
CareFusion
Taian Character
Skyepharma

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Pulmonary Drug Delivery Systems consumption (value & volume) by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.
To understand the structure of Pulmonary Drug Delivery Systems market by identifying its various subsegments.
Focuses on the key global Pulmonary Drug Delivery Systems manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Pulmonary Drug Delivery Systems with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Pulmonary Drug Delivery Systems submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

【レポートの目次】

Table of Contents

1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Data Source
1.6 Economic Indicators
1.7 Currency Considered

2 Executive Summary
2.1 World Market Overview
2.1.1 Global Pulmonary Drug Delivery Systems Consumption 2015-2025
2.1.2 Pulmonary Drug Delivery Systems Consumption CAGR by Region
2.2 Pulmonary Drug Delivery Systems Segment by Type
2.2.1 Nebulizers
2.2.2 Dry Powder Inhaler (DPI)
2.2.3 Metered Dose Inhaler (MDI)
2.3 Pulmonary Drug Delivery Systems Consumption by Type
2.3.1 Global Pulmonary Drug Delivery Systems Consumption Market Share by Type (2015-2020)
2.3.2 Global Pulmonary Drug Delivery Systems Revenue and Market Share by Type (2015-2020)
2.3.3 Global Pulmonary Drug Delivery Systems Sale Price by Type (2015-2020)
2.4 Pulmonary Drug Delivery Systems Segment by Application
2.4.1 COPD
2.4.2 Asthma
2.4.3 Others
2.5 Pulmonary Drug Delivery Systems Consumption by Application
2.5.1 Global Pulmonary Drug Delivery Systems Consumption Market Share by Type (2015-2020)
2.5.2 Global Pulmonary Drug Delivery Systems Value and Market Share by Type (2015-2020)
2.5.3 Global Pulmonary Drug Delivery Systems Sale Price by Type (2015-2020)

3 Global Pulmonary Drug Delivery Systems by Company
3.1 Global Pulmonary Drug Delivery Systems Sales Market Share by Company
3.1.1 Global Pulmonary Drug Delivery Systems Sales by Company (2018-2020)
3.1.2 Global Pulmonary Drug Delivery Systems Sales Market Share by Company (2018-2020)
3.2 Global Pulmonary Drug Delivery Systems Revenue Market Share by Company
3.2.1 Global Pulmonary Drug Delivery Systems Revenue by Company (2018-2020)
3.2.2 Global Pulmonary Drug Delivery Systems Revenue Market Share by Company (2018-2020)
3.3 Global Pulmonary Drug Delivery Systems Sale Price by Company
3.4 Global Pulmonary Drug Delivery Systems Manufacturing Base Distribution, Sales Area, Type by Company
3.4.1 Global Pulmonary Drug Delivery Systems Manufacturing Base Distribution and Sales Area by Company
3.4.2 Players Pulmonary Drug Delivery Systems Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 Pulmonary Drug Delivery Systems by Regions
4.1 Pulmonary Drug Delivery Systems by Regions
4.2 Americas Pulmonary Drug Delivery Systems Consumption Growth
4.3 APAC Pulmonary Drug Delivery Systems Consumption Growth
4.4 Europe Pulmonary Drug Delivery Systems Consumption Growth
4.5 Middle East & Africa Pulmonary Drug Delivery Systems Consumption Growth

5 Americas
5.1 Americas Pulmonary Drug Delivery Systems Consumption by Countries
5.1.1 Americas Pulmonary Drug Delivery Systems Consumption by Countries (2015-2020)
5.1.2 Americas Pulmonary Drug Delivery Systems Value by Countries (2015-2020)
5.2 Americas Pulmonary Drug Delivery Systems Consumption by Type
5.3 Americas Pulmonary Drug Delivery Systems Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
5.8 Key Economic Indicators of Few Americas Countries

6 APAC
6.1 APAC Pulmonary Drug Delivery Systems Consumption by Regions
6.1.1 APAC Pulmonary Drug Delivery Systems Consumption by Regions (2015-2020)
6.1.2 APAC Pulmonary Drug Delivery Systems Value by Regions (2015-2020)
6.2 APAC Pulmonary Drug Delivery Systems Consumption by Type
6.3 APAC Pulmonary Drug Delivery Systems Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Regions

7 Europe
7.1 Europe Pulmonary Drug Delivery Systems by Countries
7.1.1 Europe Pulmonary Drug Delivery Systems Consumption by Countries (2015-2020)
7.1.2 Europe Pulmonary Drug Delivery Systems Value by Countries (2015-2020)
7.2 Europe Pulmonary Drug Delivery Systems Consumption by Type
7.3 Europe Pulmonary Drug Delivery Systems Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa
8.1 Middle East & Africa Pulmonary Drug Delivery Systems by Countries
8.1.1 Middle East & Africa Pulmonary Drug Delivery Systems Consumption by Countries (2015-2020)
8.1.2 Middle East & Africa Pulmonary Drug Delivery Systems Value by Countries (2015-2020)
8.2 Middle East & Africa Pulmonary Drug Delivery Systems Consumption by Type
8.3 Middle East & Africa Pulmonary Drug Delivery Systems Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Pulmonary Drug Delivery Systems Distributors
10.3 Pulmonary Drug Delivery Systems Customer

11 Global Pulmonary Drug Delivery Systems Market Forecast
11.1 Global Pulmonary Drug Delivery Systems Consumption Forecast (2021-2025)
11.2 Global Pulmonary Drug Delivery Systems Forecast by Regions
11.2.1 Global Pulmonary Drug Delivery Systems Forecast by Regions (2021-2025)
11.2.2 Global Pulmonary Drug Delivery Systems Value Forecast by Regions (2021-2025)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.5.6 Spain Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Pulmonary Drug Delivery Systems Forecast by Type
11.8 Global Pulmonary Drug Delivery Systems Forecast by Application

12 Key Players Analysis
12.1 3M
12.1.1 Company Information
12.1.2 Pulmonary Drug Delivery Systems Product Offered
12.1.3 3M Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2018-2020)
12.1.4 Main Business Overview
12.1.5 3M Latest Developments
12.2 Omron Healthcare
12.2.1 Company Information
12.2.2 Pulmonary Drug Delivery Systems Product Offered
12.2.3 Omron Healthcare Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2018-2020)
12.2.4 Main Business Overview
12.2.5 Omron Healthcare Latest Developments
12.3 GSK
12.3.1 Company Information
12.3.2 Pulmonary Drug Delivery Systems Product Offered
12.3.3 GSK Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2018-2020)
12.3.4 Main Business Overview
12.3.5 GSK Latest Developments
12.4 Cipla
12.4.1 Company Information
12.4.2 Pulmonary Drug Delivery Systems Product Offered
12.4.3 Cipla Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2018-2020)
12.4.4 Main Business Overview
12.4.5 Cipla Latest Developments
12.5 Chiesi
12.5.1 Company Information
12.5.2 Pulmonary Drug Delivery Systems Product Offered
12.5.3 Chiesi Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2018-2020)
12.5.4 Main Business Overview
12.5.5 Chiesi Latest Developments
12.6 AstraZeneca
12.6.1 Company Information
12.6.2 Pulmonary Drug Delivery Systems Product Offered
12.6.3 AstraZeneca Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2018-2020)
12.6.4 Main Business Overview
12.6.5 AstraZeneca Latest Developments
12.7 Novartis
12.7.1 Company Information
12.7.2 Pulmonary Drug Delivery Systems Product Offered
12.7.3 Novartis Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2018-2020)
12.7.4 Main Business Overview
12.7.5 Novartis Latest Developments
12.8 Boehringer Ingelheim
12.8.1 Company Information
12.8.2 Pulmonary Drug Delivery Systems Product Offered
12.8.3 Boehringer Ingelheim Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2018-2020)
12.8.4 Main Business Overview
12.8.5 Boehringer Ingelheim Latest Developments
12.9 Philips Respironics
12.9.1 Company Information
12.9.2 Pulmonary Drug Delivery Systems Product Offered
12.9.3 Philips Respironics Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2018-2020)
12.9.4 Main Business Overview
12.9.5 Philips Respironics Latest Developments
12.10 Aptar
12.10.1 Company Information
12.10.2 Pulmonary Drug Delivery Systems Product Offered
12.10.3 Aptar Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2018-2020)
12.10.4 Main Business Overview
12.10.5 Aptar Latest Developments
12.11 Chia Tai Tianqing
12.11.1 Company Information
12.11.2 Pulmonary Drug Delivery Systems Product Offered
12.11.3 Chia Tai Tianqing Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2018-2020)
12.11.4 Main Business Overview
12.11.5 Chia Tai Tianqing Latest Developments
12.12 PARI
12.12.1 Company Information
12.12.2 Pulmonary Drug Delivery Systems Product Offered
12.12.3 PARI Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2018-2020)
12.12.4 Main Business Overview
12.12.5 PARI Latest Developments
12.13 Shanghai Huarui
12.13.1 Company Information
12.13.2 Pulmonary Drug Delivery Systems Product Offered
12.13.3 Shanghai Huarui Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2018-2020)
12.13.4 Main Business Overview
12.13.5 Shanghai Huarui Latest Developments
12.14 CareFusion
12.14.1 Company Information
12.14.2 Pulmonary Drug Delivery Systems Product Offered
12.14.3 CareFusion Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2018-2020)
12.14.4 Main Business Overview
12.14.5 CareFusion Latest Developments
12.15 Taian Character
12.15.1 Company Information
12.15.2 Pulmonary Drug Delivery Systems Product Offered
12.15.3 Taian Character Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2018-2020)
12.15.4 Main Business Overview
12.15.5 Taian Character Latest Developments
12.16 Skyepharma
12.16.1 Company Information
12.16.2 Pulmonary Drug Delivery Systems Product Offered
12.16.3 Skyepharma Pulmonary Drug Delivery Systems Sales, Revenue, Price and Gross Margin (2018-2020)
12.16.4 Main Business Overview
12.16.5 Skyepharma Latest Developments

13 Research Findings and Conclusion



★調査レポート[世界の肺薬物送達システム市場2020-2025:ネブライザー、ドライパウダー吸入器(DPI)、定量吸入器(MDI)] (コード:LPI20AP6682)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の肺薬物送達システム市場2020-2025:ネブライザー、ドライパウダー吸入器(DPI)、定量吸入器(MDI)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆